We administered liposome-encapsulated all-trans retinoic acid (L-ATRA) to 48 patients with refractory hematologic malignancies using an every-other-day schedule for 28 days and doses of 15 to 175 mg/m2. In 19 patients, pharmacology studies were conducted after the first (day 1) and seventh (day 15) doses. In contrast to the decline in tretinoin concentration seen within 3 to 4 days of administration of daily oral ATRA, there were no differences between the area under the curve (AUC) of tretinoin concentration versus time on day 1 and day 15 ( P = .98, Wilcoxon signed-rank test). Peak day 1 concentrations after 15 mg/m2 were higher than those reported after 45 mg/m2 oral ATRA. Six patients with relapsed acute promyelocytic leukemia (APL) were treated. Three, each in first relapse and at least year from the last exposure to oral ATRA, achieved a complete response (CR).
I all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL) are brief if ATRA is continued without addition of chemotherapy.'.* One possible explanation for this acquired resistance to ATRA is a decrease in the concentration of the drug presented to retinoic acid receptors in the cell n u c l e~s .~ Consistent with this hypothesis are observations, both in patients with APL4 and patients with other cancer^,^ that plasma ATRA concentrations start to decline often within 3 to 4 days of beginning oral ATRA.
Encapsulation of ATRA in liposomes (L-ATRA) provides a parenteral ATRA preparation that has been shown in rats to decrease metabolism of ATRA by hepatic microsomes. ' The liposomal nature of the product may also result in less ATRA going to the skin,' a major site of cellular retinoic acid binding proteins. 8 Perhaps as a result of these effects, ATRA concentrations are maintained longer in rats given L-ATRA than in rats given the same amount of oral ATRA.h,9 Alterations in biodistribution may also be responsible for the reduced toxicity seen on a milligram-to-milligram basis in rats given L-ATRA versus oral ATRA. ' With these animal data as a backdrop, we have conducted a phase I trial of L-ATRA in patients with refractory hematologic malignancies. Concentrations of ATRA in blood were
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1996 by The American Society of Hematology.
0OO6-4971/96/8709-00I 3$3.00/0
Disease recurred in two (one at 3 months despite maintenance L-ATRA and similarity in tretinoin AUC on days 1 and 85, and the other at 5 months, 2 months after discontinuation of L-ATRA) and the third was transplanted 1 month into CR. The three nonresponders were in at least a second relapse and failed to respond to oral ATRA before or immediately after receiving L -A m . Severe toxicity developed in three of eight patients treated at 175 mg/m2 (joint pains in two, skin in one). The maximum tolerated dose (MTD) was determined to be 140 mg/m2, at which dose grade 2 toxicity (primarily headache and skin) occurred in eight of eight patients, but grade 3 to 4 toxicity in none. Compared with oral ATRA, L-ATRA apparently results in greater exposure to tretinoin and for a longer time. 0 1996 by The American Society of Hematology. measured on day 1 and day 15 of the study in 19 of 48 patients. Like oral ATRA, L-ATRA induces differentiation in vitro in cells from patients with APL,'" and the six patients with relapsed APL who received L-ATRA are thus of particular interest.
PATIENTS AND METHODS
Standard phase 1 entry criteria were used: no known curative treatment for the patient's malignancy was available, at least 4 weeks had elapsed since the last chemotherapy, serum bilirubin and creatinine each were less than 1.6 mg/dL, and Zubrod performance status was 0 to 3. Pregnant women and patients with circulating blast counts above 5,OOO/pL were excluded. Forty-eight patients were enrolled beginning in April 1993. Six had relapsed APL, 13 relapsed acute myelogenous leukemia or myelodysplastic syndrome, one relapsed T-cell acute lymphocytic leukemia, 14 T-cell lymphoma (seven cutaneous and seven systemic), and 14 B-cell lymphoma. The disproportionate number of T-cell lymphoma patients reflected our desire to treat these patients, given the activity of oral ATRA in T-cell lymphomas.
L-ATRA (Aronex Pharmaceuticals Inc, The Woodlands, TX) was given over I half-hour every other day for 28 days. The every-otherday schedule was based on animal data indicating that the half-life of L-ATRA in tissue exceeded 39 hours, with concentrations at this time exceeding those necessary to differentiate APL cells in vitro.'."' Responding patients could continue to receive L-ATRA. The dose given to the initial patients was 15 mg/m2, and subsequent patients received 30,60,75,90, 1 IO, 140, and 175 mg/m2. Given the variable absorption of oral ATRA,"." it is difficult to translate a given L-ATRA dose into an equivalent oral ATRA dose. Typical phase I guidelines governed dose-escalation: new patients were treated at the next higher dose if grade 3 to 4 toxicity (National Cancer Institute criteria) was observed in none of three or one of six, patients at the previous dose, and if such toxicity was seen in more than two of six patients at a given dose, that dose was considered above the maximum tolerated dose (MTD), with the previous dose called the MTD if toxicity was noted in not more than one of three or two of six patients at that dose. With three exceptions, each patient received only one dose level.
In 19 patients (three at 15, two at 30, three at 60, three at 75, two at 90, one at 110, three at 140, and two at 175 mg/m*), blood samples were obtained before infusion, 15 and day 15 (after the seventh dose of L-ATRA). In an additional patient with APL, blood samples were obtained at the above times on day 1 and day 85 (after the thirty-second dose).
Analysis of ATRA in whole blood was performed using highperformance liquid chromatography as previously de~cribed.6.~ The lower limit of detection was 0.2 pg ATRA/mL blood. Standard pharmacokinetic parameters were derived using nonlinear regression analysis9 (RSTRIP; Micro-Math Inc, Salt Lake City, UT).
Confidence intervals for binomial parameters were computed using the method of Three patients were treated at two different doses: one received 30 and then 60 mg/m2, one 75 and then 60 mg/m2 with severe toxicity (hypotension) at both doses, and one 175 and then 140 mg/m2 with severe toxicity (joint pain) at 175 but not at 140 mglm'. regression analysis, a weighted least-squares procedure was used to account for heteroscedasticity, using the inverse of the empirical variance computed from repeated measurements of the response variable at each dose as the weight at that dose. For each model, the pure error mean squares was used to estimate the variance in computing confidence bands for the predicted line. Model goodnessof-fit was assessed by residual plots on dose and on predicted AUC, Q-Q plots, model RZ, and individual coefficient P values. All computations were carried out in S plus on a SUN SPARC station 20 desktop computer (Sun Microsystems, Mountain View, CA). Table 1 shows the number of patients treated at the various doses. With the exception of one patient at 75 mg/m', the same patient after dose-reduction to 60 mg/m', and three patients at 175 mg/m', all patients who did not complete the prescribed 28 days of treatment went off study because of progressive disease ( Table 1) . Side effects occurred in all 48 patients (95% confidence limit, 93% to 100%). The most common was headache, which occurred in 71% of patients (95% confidence limit, 56% to 81%). Dry skin and nausea/ vomiting were reported in 31% (95% confidence limit, 20% to 46%) and 21% (95% confidence limit, 12% to 35%), respectively. The majority of side effects were mild or moderate (with the exception of one case of hypotension at 75 mg/m' and again at 60 mg/m'. and one case of severe headache at 110 mg/m') until a dose of 175 mg/m' was reached ( Table 1) . Eight patients began treatment at this dose, of whom two were removed from study because of progressive disease without severe toxicity (after two and 10 doses, respectively) and three because of severe toxicity, leaving three patients who completed 28 days without severe toxicity. The dose-limiting side effects in the three who were removed because of toxicity were joint pain in two and exfoliative rash in one. One of the patients who had severe joint pain at 175 mg/m' had therapy resumed at 140 mg/m' 5 days later, after recovery from toxicity. The patient completed 28 days at 140 mg/m2 without further grade 3 to 4 toxicity. After the three patients developed grade 3 to 4 toxicity at 175 mg/m', a second cohort (four patients) was treated at 140 mg/m'. Although none of the total of eight patients at 140 mg/m' (seven completing toxicity, all had grade 2 toxicity principally consisting of headache and rash, and in one patient, hearing loss. Based on this experience, we considered 140 mg/m2 given every other day for 28 days the MTD. Table 2 indicates that AUC values (calculated from the end of infusion until infinity) are relatively similar on day 1 and 15, ie, after the first and seventh doses of the liposomal preparation. Indeed, there is no statistical difference between day 1 and day 15 AUCs (P = .98), with the lower mean day 15 value at 90 mg/m2 reflecting one patient whose day 1 and day 15 values were 1,213.5 and 870.3 pg min/mL, respectively, with the respective values in the second patient at this dose being 259.4 and 207.2 pg"in/mL. A third patient treated at 90 mg/m2 had APL in relapse, responded to L-ATRA, and as a result continued to receive 90 mg/m2. Blood samples were obtained on day 1 and day 85 (although not on day 15) with an AUC of 119.5 pg -min/mL on day 1 and 165.2 pg min/mL on day 85.
RES U LTS
Model-fitting using weighted least-squares indicated that the relationship between AUC on day 15 (AUC 15) and dose was quadratic, specifically of the form mean AUC 15 = Po + PIX + p2X2, where X = dose -mean dose, rather than linear, ie, of the form mean AUC 15 = Po + plX. The model R2 was 95.9%, ie, 95.9% of the variability in AUC 15 was explained by its quadratic regression on dose. The P value for the test of the hypothesis that the coefficient P2 of X2 equals zero, ie, that a linear regression rather than a quadratic regression is appropriate, was ,007. This strongly indicates that p2 of X2 is not zero, and thus the regression of AUC on dose is quadratic rather than linear. Similarly, for AUC on day 1 (AUC 1) as a quadratic on dose R2 was 89.3% with a P value of 0.36 for the quadratic term. Figures 1 and 2 depict the relationship between dose and AUC 15 and AUC 1, respectively. Given the high degree of variability in the data, particularly at higher does (eg, as illustrated in Fig 2) , it is not unlikely that patients treated at different does, eg, 175 and 75 mg/m2, may have similar AUC values. However, it is important to note that the regression model accounts both for average behavior (represented by solid lines in the figures, illustrating the predicted mean AUC values as a function of dose) and for variability (dashed lines, representing the 95% confidence bands).
The elimination of ATRA from blood was found to fit a
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one-compartment model in 29 analyses and a two-compartment model in 11 analyses (19 patients studied on day 1 and again on day 15, and one patient studied on day 1 and day 85). Occasionally, the same patient's data could best be described by a two-compartment model on day l and a onecompartment model on day 15 (or vice versa). When present, values for initial L-ATRA half-life (tlI2a) were low, ranging from 0.2 to 11.0 minutes. There were no statistical differences between day 1 and day 15 values for terminal-phase half-life (tl& ( P = .98) or clearance of ATRA from blood ( P = 32). No metabolites of ATRA, eg, 4-oxo-retinoic acid glucuronide, were detected in blood. Urinary concentrations were not studied. Peak tretinoin concentrations are shown in Table 2 ; there were no differences between day 1 and day 15 values ( P = .4) The Vd of L-ATRA approximated total body water, with no difference between day 1 and day 15 values for apparent volume of distribution expressed on a per-kilogram-body-weight basis ( P = S9).
As noted earlier and illustrated in Table 3 , we treated six patients with APL in relapse. Disease in the first three, who received relatively low doses, was in second or greater relapse. The second patient had failed to respond to oral ATRA 4 months before receiving L-ATRA, and after failing to respond to L-ATRA, which was given for at least 28 days, both the first and third patients failed to respond to oral ATRA. In contrast, disease in the fourth, fifth, and sixth patients, in each of whom L-ATRA produced a complete response (CR), was at a relatively earlier stage and the interval since last receiving ATRA was at least 12 months. Of the six patients, three had pharmacology studies, including two nonresponders and one responder. Both the lowest and highest AUC values were seen in nonresponders ( Table 3) .
The pattern of response in all responding APL patients was similar and is illustrated in Fig 3. An initial increase in neutrophils was followed by a decrease and then a second increase coincident with an increase in platelet count. There was a progressive decrease in marrow promyelocytes concomitant with an increase in more mature forms, a pattern similar to that seen after oral ATRA. None of the six patients developed the ATRA syndrome (95% confidence limit, 0% to 39%; reported incidence of ATRA syndrome after oral ATRA, -25%). All three responding patients were maintained on thrice-weekly (every Monday, Wednesday, and Friday) L-ATRA at their induction dose. Disease in the first
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For reappeared during maintenance treatment after a CR of 3 months, despite the similarity in day 1 and day 85 tretinoin AUC values noted earlier. The second received 3 months of maintenance L-ATRA; 2 months after discontinuation of L-ATRA, his disease reappeared and an allogeneic marrow transplant was performed. The third remained in remission for l month, at which time she received an allogeneic marrow transplant. Six minor, transient responses have occurred among 14 patients with T-cell lymphomas, most often (five of five, two not assessable for response because of toxicity at 175 mg/ m2) in patients with cutaneous T-cell lymphoma. No other responses have occurred while 11 of 14 patients with non-T-cell lymphomas have had progressive disease.
than peak concentrations reported after 45 mg/m' oral ATRA, reflecting, at least to some extent, the limited bioavailability of the oral preparation,"*'' suggests that exposure to ATRA is likely to be greater after L-ATRA than after oral A m , certainly at the usually used dose of the latter, 45 mg/m2 daily. Furthermore, the quadratic relationship between AUC and dose suggests that accumulation of ATRA occurs, although we have no direct evidence that this takes place at any site, for example, the bone marrow.
The mechanism underlying the stability in AUC between day 1 and day 15 is the presumed ability of the liposomal preparation to bypass metabolism by hepatic microsomes. Although no metabolites of ATRA, eg, 4-oxo-retinoic acid glucuronide, were detected in blood, a failure to detect such metabolites does not imply that L-ATRA is not metabolized, given that we did not assay urinary metabolites of L-ATRA.
DISCUSSION
Our results indicate that liposomal encapsulation of ATRA appears to permit maintenance of tretinoin concentrations longer than is currently possible with standard oral preparations of ATRA (compare Table 2 with data in Muindi et al'). This result, together with the data in Table 4 indicating that the peak concentration at the lowest L-ATRA dose administered (15 mg/m') averaged two to three times higher 
cell membranes, and (3) phagocytes after ingestion. Therefore, to assess the total available drug, we measure the drug level in whole blood. It should be noted that hydrophobic drugs like ATRA do not leak out of liposomes, but instead exchange as described earlier,I4 and because of its hydrophobic nature, ATRA is technically not "free" in the circ~lation.'~ Clearly, what is critical is the amount of intracellular ATRA, and correlations remain to be established For personal use only. on September 14, 2017. by guest www.bloodjournal.org From between the amount as measured in either blood or plasma and the amount available to tumor cells; for example, it is unknown if ATRA bound to membranes or ingested by phagocytes is available to tumor cells. It should also be noted that with both liposomal and standard oral preparations there is considerable patient-to-patient variation in pharmacokinetics. However, with L-ATRA, the significant variation in bioavailability seen with the oral preparation"*'2 is obviously not an issue. The lowest tretinoin concentration (-2.3 pmoV L) observed at the lowest L-ATRA dose (15 mg/m') approximates the concentrations needed to induce differentiation in APL cells in vitro (2.0 pol/L).'"
The MTD of L-ATRA was found to be 140 mg/m2 every other day for 28 days. At this dose, headache and dry skin were frequent but not dose-limiting. The skin toxicity is inconsistent with the hypothesis that liposomal encapsulation will retard ATRA delivery to the skin. Indeed, the toxicity profiles of L-ATRA and oral ATRA (MTD 150 mg/m' daily for 6 weeks") are similar (with headache, dry skin, and nausedvomiting being the prominent side effects with both preparations), and it is interesting that the much greater AUC after administration of L-ATRA does not result in much greater toxicity.
This raises the question of whether the greater exposure to ATRA presumably afforded by the use of L-ATRA will have clinical benefit relative to oral ATRA. A major impetus for the development of L-ATRA was the observation that at disease relapse patients with APL had lower serum tretinoin concentrations than when initially treated with oral ATRA," together with observations that at relapse the APL cells of these patients remained responsive to tretinoin in vitro," although this latter finding has been questioned.I6 If both observations were correct, maintenance of tretinoin concentrations for longer periods (eg, with L-ATRA) might avert relapse. Our results indicate that L-ATRA has activity in APL. However, it should be noted that the three patients in whom L-ATRA produced a CR were perhaps also likely to have responded had they received oral ATRA, given the relatively early stage of their disease together with the relatively long interval since last receiving oral ATRA ( Table  4) . ' In contrast, disease in the three patients who did not respond to L-ATRA was more advanced. Furthermore, given the small number of patients, there was no strict relation between AUC and response ( Table 3) , and a relapse occurred despite similar AUC values on day 1 and day 85. It would not be surprising if the failure to maintain tretinoin concentrations were only one (if one) mechanism underlying the development of resistance to ATRA. Although the future utility of L-ATRA in APL is thus uncertain, the favorable pharmacologic profile of the material will permit determination of whether a change in pharmacologic properties results in more effective treatment of APL.
